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Abstract 
Background and Purpose: The aim of this study was to investigate for a possible 
association between both pre-stroke CHA2DS2-VASc score and the severity of stroke at 
presentation as well as disability and mortality at 90 days in patients with acute stroke 
and atrial fibrillation (AF).   
Methods: This prospective study enrolled consecutive patients with acute ischemic 
stroke, AF and assessment of pre-stroke CHA2DS2-VASc score. Severity of stroke was 
assessed at admission by the National Institute of Health Stroke Scale (NIHSS) score, 
(severe stroke: NIHSS≥10). Disability and mortality at 90 days were assessed by the 
modified Rankin Scale (mRS<3 or ≥3). Multiple logistic regression was used to correlate 
pre-stroke CHA2DS2-VASc and severity of stroke as well as disability and mortality at 90 
days. 
Results: Of the 1.020 patients included in the analysis, 606 patients had an admission 
NIHSS score lower and 414 patients higher than 10. At 90 days, 510 patients had 
mRS≥3. A linear correlation was found between pre-stroke CHA2DS2-VASc score and 
severity of stroke (p=0.001). On multivariate analysis, CHA2DS2-VASc score correlated 
with the severity of stroke (p=0.041) and adverse functional outcome (mRS≥3) (p=0.001). 
A logistic regression with the ROC graph procedure (C statistic) evidenced an area under 
the curve of 0.60 (p=0.0001) for severe stroke.  Furthermore, a correlation was found 
between pre-stroke CHA2DS2-VASc score and the lesion size.   
Conclusions: In patients with AF, in addition to the risk of stroke, a high CHA2DS2-VASc 
score was independently associated with both stroke severity at onset and disability and 
mortality at 90 days.
 Background and Purpose 
In patients with atrial fibrillation (AF), current guidelines recommend using the 
CHA2DS2-VASc score to assess the risk of stroke1. In retrospective studies CHA2DS2-
VASc score have been suggested as a predictor of severity of stroke at admission and 
poor outcome2–4.   
The aim of this study was to investigate for a possible association between both pre-
stroke CHA2DS2-VASc score and the severity of stroke at presentation as well as 
disability and mortality at 90 days in patients with acute stroke and atrial fibrillation 
(AF).   
 
Methods 
Data for this analysis were extracted from the database of a prospective multicentre 
study which had enrolled consecutive patients with acute stroke and AF (the RAF 
study)5.  This study, carried out between January 2012 and March 2014, enrolled 1,029 
consecutive patients from 29 Stroke Units throughout Europe and Asia.  
Pre-stroke CHA2DS2-VASc score was evaluated as previously described5. On admission, 
the severity of acute stroke was assessed using the National Institutes of Health Stroke 
Scale (NIHSS); all investigators were certified on the use of this scale. Disability and 
mortality at 90 days were assessed using the modified Rankin Scale (mRS).  
Data on known stroke risk factors were collected as reported in the main paper5.  
A cerebral computed tomography (CT) or magnetic resonance (MR) was performed on 
admission for all patients to exclude intracranial hemorrhage. A second cerebral CT scan 
or MR was performed 48-72 h from stroke onset. The sites and sizes of the qualifying 
infarcts were determined based on standard templates 6,7 as previously described 5. 
Statistical analysis 
The primary pre-specified a priori study question was if CHA2DS2-VASc score had been 
associated with stroke severity assessed by NIHSS at onset. Then, as a post-hoc analysis, 
possible correlations between CHA2DS2-VASc scores and outcome assessed by mRS and 
between CHA2DS2-VASc scores and lesion size were investigated for. 
The admission NIHSS score was evaluated both as a continuous variable for the 
correlation coefficient r analysis, and dichotomized variables (severe stroke NIHSS≥10) 
for the multivariate analysis.  
The correlation coefficient r, Pearson product-moment correlation coefficient, was used to 
measure the strength of the linear association between CHA2DS2-VASc before the event 
and NIHSS score on admission (as continuous variable).  
Correlations between pre-stroke CHA2DS2-VASc and severity of stroke were sought by 
multiple logistic regression after adjusting for the following variables: smoking, 
hyperlipidemia, alcohol abuse and use of statins in addition to CHA2DS2-VASc.  
Thereafter, the probability of a receiver-operating characteristic (ROC) curve against 
NIHSS≥10 as dependent variable was plotted. The area under this curve suggests an 
ability of the CHA2DS2-VASc score to predict for severe stroke, which is also referred to 
as the C-statistic (Harrell’s C). 
In addition, a multiple logistic regression model including components singularly of the 
CHA2DS2-VASc was performed.  
Stroke was defined as either non-disabling (mRS 0 to 2) or disabling (mRS 3 to 5). 
The factors evaluated as independent predictors of 3 month adverse outcome (defined as 
modified Rankin scale 3 or death) were assessed using multiple logistic regression 
analysis. The variables included in the model were CHA2DS2-VASc score, cardiovascular 
risk factors, reperfusion therapy and severity of stroke on admission according to NIHSS 
score.  
The sites and sizes of the qualifying infarcts showed at CT scan were determined based 
on standard templates as follows: (1) small, when a lesion was ≤1.5 cm in the anterior or 
posterior circulation, (2) medium, when a lesion was in a cortical superficial branch of 
middle cerebral artery [MCA], in the MCA deep branch, in the internal border zone 
territories, in a cortical superficial branch of posterior cerebral artery [PCA], in the PCA 
branch or in a cortical superficial branch of the anterior cerebral artery [ACA]), (3) large 
anterior, when a lesion involved the complete territory of ACM, ACP, or ACA, in 2 cortical 
superficial branches of MCA, in a cortical superficial branch of MCA associated to the 
MCA deep branch, or in more than 1 artery territory [eg, MCA associated to ACA 
territories]), (4) large posterior, when a lesion was ≥1.5 cm in the brain stem or 
cerebellum8.  
A possible correlation between lesion size and CHA2DS2-VASc score was investigated for 
using a -squared (p for trend). 
Results:  
Overall, 1,029 consecutive patients were included in the study (mean age 77.2 ± 9.5 
years; 560 females and 469 males). The distribution of CHA2DS2-VASc score in the study 
patients is reported in the Table 1.  
Nine patients were excluded from the analysis as their NIHSS score was not available. Of 
the 1.020 patients included in the analysis, 606 patients had an admission NIHSS score 
lower and 414 patients higher than 10. The mean NIHSS score for each of the CHA2DS2-
VASc scores are reported in the Table 1 (p=0.071).  A linear correlation was found 
between severity of stroke and CHA2DS2-VASc score (r2 0.010, p=0.001) (fig. 1). On 
multivariate analysis, CHA2DS2-VASc score correlated with the severity of stroke (OR 
1.084, 95% CI 1.003-1.172, p=0.041, for each one point increase). Considering the 
modest correlation, a logistic regression with a ROC graph procedure, to get the c 
statistic, was performed and it evidenced that the area under the curve was 0.60 (0.56-
0.63), p=0.0001 for severe stroke.   
When factors included in the CHA2DS2-VASc score were assessed individually for a 
correlation between stroke severity, only increasing age and female sex resulted being 
significantly correlated to stroke severity according to NIHSS (p=0.007 and p =0.001, 
respectively) (Table 2).  
A correlation was also found between pre-stroke CHA2DS2-VASc score and lesion size. 
After excluding patients treated with revascularization, 70% of patients with CHA2DS2-
VASc score of 8 or 9 had a medium-large lesion, while 70% of patients with CHA2DS2-
VASc score of 0 had a small lesion (Figure 2, p for trend=0.042). 
At 90-days, 1.019 patients were available for the functional outcome analysis (10 
patients were lost at follow-up). The correlation between pre-stroke CHA2DS2-VASc score 
and 90 day outcome is reported in Table 1.    
On multivariate analysis, both NIHSS score on admission and CHA2DS2-VASc score were 
correlated with disability and mortality at 90 days (mRS≥3) (OR 1.236, 95% CI 1.197-
1.277, p<0.0001; OR 1.278; 95% CI 1.100-1.484, p=0.001 respectively for each one point 
increase).   
The administration of thrombolytic therapy and the use of statins at admission resulted 
being independently correlated with better outcome (OR 0.313, 95% CI 0.204-0.481, 
p<0.0001; OR 0.585, 95% CI 0.354-0.967, p=0.036; respectively).  
 
Discussion:  
The results of our study found correlations between pre-stroke CHA2DS2-VASc score and 
severity of stroke at presentation, according to NIHSS, as well as between CHA2DS2-
VASc score and 90-day mortality and disability, as measured by mRS.  
Therein, indicating that a higher CHA2DS2-VASc score is predictive of a worse outcome.  
Moreover, in post-hoc analyses we also found, first, a correlation between higher 
CHA2DS2-VASc score and greater lesion size. This finding could support previous 
studies that have reported an association between CHA2DS2-VASc score and major 
vessel occlusion in patients with acute ischemic stroke and AF 9.  Second, our study 
results also is in line with past studies reporting that among risk factors, age and female 
sex are more predictive of severe stroke10,11.  
A strength of this study was that several stroke assessment scores were prospectively 
utilized, and each of these scores were correlated to the CHA2DS2-VASc score. Whereas, 
several past studies were retrospective and used only a single assessment score2–4,12–14.   
In conclusion, we found an increasing CHA2DS2-VASc score in AF patients predicted a 
more severe stroke at presentation, leading to a higher rate of disability and mortality at 
90 days. This result highlights the need for physicians to more regularly investigate for 
AF in patients with other known vascular risk factors, especially increasing age and 
female sex.  
 
  
Table 1: Stroke severity (NIHSS) and 90 day outcome according to pre-stroke CHA2DS2-
VASc score 
CHA2DS2-VASc score Pre-stroke CHA2DS2-
VASc  
(n=1029) 
 
NIHSS at admission 
(mean)^ 
(n=1020**) 
90-day mRS score3* 
(n=1019***) 
0 
 
17 (1.7%) 5.18 ± 5.75 4/17 (23.5%) 
1 
 
54 (5.2%) 8.30 ± 8.16 16/53 (30.2%) 
2 
 
91 (8.9%) 8.31 ± 6.70 34/90 (37.7%) 
3 
 
200 (19.4%) 8.86 ± 7.10 81/198 (40.9%) 
4 
 
243 (23.6%) 9.12 ± 7.22 125/242 (51.6%) 
5 
 
206 (20.0%) 9.67 ± 7.73 113/202 (55.9%) 
6 
 
129 (12.8%) 9.70 ± 6.50 78/129 (60.5%) 
7 
 
66 (6.4%) 10.30 ± 8.20 43/65 (66.1%) 
8-9 
 
23 (2.2%) 12.09 ± 6.68 16/23 (69.6%) 
 
^p for trend=0.071 
 
*p for trend=0.0001 
 
** Nine patients were excluded from the analysis as their NIHSS score was not available 
***1019 patients were available for the final functional outcome analysis (10 patients 
were lost at follow-up)  
 
Table 2. Multivariate analysis for correlation of stroke severity and any of each 
component of CHA2DS2-VASC score. 
 OR P 95% CI 
Age (for each year increase) 1.020 0.007 1.005-1035 
Sex 0.367 0.001 0.515-0.175 
Diabetes 1.172 0.296 0.870-1.575 
Hypertension  0.759 0.110 0.542-1.065 
Stroke/TIA/Thromboembolism 0.972 0.849 0.723-1.306 
History 
Congestive Heart Failure  1.049 0.777 0.753-1.462 
Vascular Disease  1.034 0.832 0.760-1.406 
 
 
Fig. 1. Linear correlation between NIHSS at admission and CHA2DS2-VASC score. 
 
  
Figure 2:  CHA2DS2-VASC score and lesion size (excluding patients treated with 
revascularization). 
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* p for trend=0.042  
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